Clopidogrel response: Head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting  by Cuisset, Thomas et al.
Archives of Cardiovascular Disease (2010) 103, 39—45
CLINICAL RESEARCH
Clopidogrel response: Head-to-head comparison of
different platelet assays to identify clopidogrel non
responder patients after coronary stenting
Réponse au clopidogrel : comparaison de différents tests plaquettaires dans
l’identiﬁcation des patients non répondeurs après angioplastie coronaire
Thomas Cuisseta,b,∗, Corinne Frereb,c,
Raphael Poyeta, Jacques Quilici a,
Bénédicte Gaboritb,c, Laurent Bali a, Olivier Brissya,
Marc Lamberta, Pierre-Emmanuel Morangeb,c,
Marie-Christine Alessib,c, Jean-Louis Bonneta
a Department of Cardiology, CHU Timone, Marseille, France
b UMR 626, Inserm, faculté de médecine, CHU Timone, 13385 Marseille, France
c Laboratoire d’hématologie, CHU Timone, 13385 Marseille, France
Received 12 June 2009; received in revised form 4 November 2009; accepted 5 November 2009
KEYWORDS
Acute coronary
syndromes;
Stenting;
Clopidogrel response;
Platelet function
testing
Summary
Objectives.— We investigated the agreement between different platelet tests to identify clopi-
dogrel non response.
Background.— Biological deﬁnition of clopidogrel non response remains controversial. Different
platelet tests have been linked with recurrent ischemic events and proposed for daily practice.
Methods.— We prospectively investigated the agreement of platelet tests to isolate clopi-
dogrel non response in patients receiving high 150mg clopidogrel maintenance dose after
coronary stenting. Clopidogrel response was assessed with ADP-induced aggregation (ADP-Ag)
(non response if > 70%), Platelet reactivity index VASP (PRI VASP) (non response if > 50%) and
Verify Now Point-of-care assay (VN) (non response if PRU > 240 AU).
Results.— Seventy consecutive patients were included. The rates of non-responders were
respectively: 13% (n = 9) with the ADP-Ag, 39% (n = 27) with the PRI VASP and 33% (n = 23) with the
VN. We observed signiﬁcant correlation between different platelet tests assessing clopidogrel
response: r = 0.55 (p < 0.0001) for ADP-Ag and PRI VASP, r = 0.64 (p < 0.0001) for ADP-Ag and
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Conclusion.— L’évaluation de la réponse au clopidogrel et l’identiﬁcation des patients non
épen
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ntroduction
everal studies have reported interindividual variability in
latelet response to clopidogrel [1] with clinical relevance
2—9]. However, no method of quantiﬁcation of platelet
unction inhibition by clopidogrel has consensually been
ecommended. There is a clinical need to have a reli-
ble platelet assay for measuring platelet function after
ntiplatelet therapy for monitoring and potentially tai-
oring antiplatelet dosing regimens to individual patients.
ight transmittance platelet aggregometry remains the gold
tandard for platelet function assessment, and elevated
latelet activation in the context of impaired response to
lopidogrel using this technique has been associated with
ecurrent ischemic events [2—4]. For response to clopido-
rel, classical aggregometry has been criticized for poor
eproducibility and lack of speciﬁcity for the P2Y12 pathway.
new ﬂow cytometric vasodilator-stimulated phosphopro-
ein (VASP) phosphorylation assay has been introduced to
easure speciﬁc inhibition of clopidogrel’s biochemical tar-
et via the P2Y12 receptor. The platelet reactivity index
ASP has been also associated with recurrent ischemic
vents after PCI [5,6]. These laboratory tests demand spe-
iﬁc knowledge and skills, requires specialized equipments,
nd is labour-intensive. Recently, point-of-care assay as
erify Now system was introduced to assess clopidogrel
esponse with clinical relevance [7—9]. However, there is
T
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a
cdante ».
s droits réservés.
ot yet a consensus, neither about the ‘‘gold standard’’
est, nor about the deﬁnition of non-response. We there-
ore designed a prospective study to assess the agreement
etween the most common threshold of ADP-Ag, PRI VASP
nd Verify Now point-of-care test to detect clopidogrel non-
esponders among clopidogrel-treated patients undergoing
oronary stenting for Non ST Elevation Acute coronary Syn-
rome (NSTE ACS).
ethods
tudy protocol
onsecutive patients admitted for NSTE ACS in our institu-
ion were eligible for this prospective study after successful
oronary stenting. NSTE ACS was deﬁned as clinical symp-
oms compatible with acute myocardial ischemia within 12 h
efore admission and at least one of the following: a new
nding of ST changes at least two leads, elevated levels of
ardiac markers or coronary artery disease as documented
y a history of revascularization or myocardial infarction.T. Cuisset et al.
VN and r = 0.59 (p < 0.0001) for PRI VASP and VN. However, using the most common thresholds,
the agreement between the difference tests was poor: 0.35 for ADP-Ag and PRI VASP, 0.36 for
ADP-Ag and VN and 0.46 for PRI VASP and VN.
Conclusion.— This study showed that assessment of platelet function inhibition by clopi-
dogrel is highly test-speciﬁc. Indeed, our results demonstrated a poor agreement between
different platelet assays and suggested that identiﬁcation of clopidogrel non responders is
test-dependent.
© 2010 Elsevier Masson SAS. All rights reserved.
Résumé
Background.— La déﬁnition biologique de la non réponse au clopidogrel reste controversée.
Différents tests plaquettaires ont été reliés au pronostic clinique et proposés pour la pratique
quotidienne.
Objectif.— Étudier la concordance entre différents tests plaquettaires pour l’identiﬁcation de
la non réponse au clopidogrel.
Méthodes.— Nous avons de fac¸on prospective évalué la concordance entre différents tests pla-
quettaires pour l’identiﬁcation de la non réponse au clopidogrel chez des patients recevant une
forte dose d’entretien de clopidogrel (150mg) après stenting coronaire. La réponse au clopi-
dogrel était évaluée par l’agrégation plaquettaire induite par l’ADP (ADP-Ag, non-réponse si
supérieure à 70%), l’indice de réactivité plaquettaire VASP (IRP VASP, non réponse si supérieure
à 50%) et le test minute VerifyNow P2Y12 (non réponse si P2Y12 reaction units > 240).
Résultats.— Soixante-dix patients consécutifs ont été inclus. Le taux de non répondeurs était :
13 % (n = 9) avec l’ADP-Ag ; 39 % (n = 27) avec l’IRP VASP ; et 33 % (n = 23) avec le test VerifyNow.
Il existait une corrélation signiﬁcative entre les différents tests : r = 0,55 (p < 0,0001) pour ADP-
Ag et IRP VASP ; r = 0,64 (p < 0,0001) pour ADP-Ag et VerifyNow ; et r = 0,59 (p < 0,0001) pour
l’IRP VASP et le VerifyNow. En revanche, utilisant les seuils les plus communément admis, la
concordance entre les différents tests était médiocre : kappa = 0,35 pour ADP-Ag et l’IRP VASP ;
0,36 pour l’ADP-Ag et le VerifyNow ; et 0,46 pour l’IRP VASP et le VerifyNow.he exclusion criteria were a history of bleeding diathesis,
ersistent ST elevation ACS, NYHA class IV, PCI or coro-
ary bypass grafting (CABG) < 3 months, contraindications to
ntiplatelet therapy, platelet count < 100G/L, and creatinin
learance < 25mL/min. Patients received oral loading doses
s 41
Table 1 Baseline characteristics of the population.
Mean age, years (mean± SD) 63.1± 11.3
Men 66%
Hypertension 47%
Diabetes mellitus 26%
Smoker 31%
Dyslipidemia 61%
Body mass index (kg/m2) 26.8± 4.3
Use of statin 82%
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•Clopidogrel response: comparison of different platelet assay
of 250mg aspirin and 600mg clopidogrel at least 12 hours
before stenting. At discharge, all patients received aspirin
75mg and clopidogrel 150mg and assessment of clopidogrel
response was performed at 1 month. The study protocol was
approved by the ethics committee of our institution, and
patients gave written informed consent for participation.
Blood samples and platelet parameters
Blood samples for testing platelet reactivity were drawn one
month after discharge from a peripheral blood sample.
ADP-Induced platelet aggregation (ADP-Ag)
The blood-citrate mixture was centrifuged at 120 g for
5min. The resulting platelet rich plasma (PRP) was kept
at room temperature for use within 1 h. The platelet
count was determined in the PRP sample and adjusted to
2.5× 108 mL-1 with homologous platelet-poor plasma (PPP).
Platelets were stimulated with ADP (10mol/L) and aggre-
gation was assessed with a PAP4 Aggregometer (Biodata
Corporation, Wellcome, Paris, France). Aggregation was
expressed as the percentage change in light transmittance
from baseline with PPP as reference. Here, we report data
on maximal intensity of platelet aggregation. We performed
one measurement for each sample. The coefﬁcient of vari-
ation of maximal intensity of platelet aggregation with ADP
was measured at 6.5%. Non-response to clopidogrel was
deﬁned as ADP-Ag > 70%, as previously proposed [2,4].
Platelet Reactivity Index VASP (PRI VASP)
To determine the VASP phosphorylation state of whole blood,
we used a standardized ﬂow cytometric assay (Platelet
VASP®; Diagnostica Stago [Biocytex], Asnières, France),
which is an adaptation of the method of Schwarz et al. [11].
A platelet reactivity index (PRI VASP) was calculated from
the median ﬂuorescence intensity (MFI) of samples incu-
bated with PGE1 or PGE1 and ADP according to the formula:
PRI VASP = [MFI (PGE1)−MFI (PGE1+ADP)/MFIPGE1]× 100.
Non-response to clopidogrel was deﬁned as PRI VASP > 50%,
as previously proposed [5].
Point of care Verify Now Assay
We used the VerifyNow P2Y12 (Accumetrics, San Diego,
CA, USA) point-of-care system, a rapid platelet-function
cartridge-based assay with speciﬁc cartridges for the P2Y12
pathway. The Verify Now P2Y12 is designed to directly
measure the effects of drugs on the P2Y12 receptor.
VerifyNow-P2Y12 assay uses prostaglandin E1 in addition to
ADP to increase intraplatelet cAMP. VerifyNow-P2Y12 assay
results are expressed in P2Y12 Reaction Units (PRU) and %
inhibition P2Y12 from baseline activation via TRAP (% inhibi-
tion P2Y12). The Verify Now analyser is designed to measure
this agglutination as an increase in light transmittance. We
used the PRU to deﬁne non-response to clopidogrel with a
PRU> 240 AU [8,9].Statistical analysis
Statistical analysis was performed with the SAS Software
(v 8.01; SPSS Inc., Chicago, IL, USA). Continuous variables
are expressed as mean± S.D. or median and interquartile
•
•Use of Beta-blockers 67%
Use of proton Pump Inhibitors 94%
ange. Categorical variables are expressed as frequencies
nd percentages. The Wilcoxon rank-sum test was used to
ompare continuous variables. Comparison between cate-
orical variables were performed using the v2-test or the
ischer’s exact test when frequencies were below ﬁve.
he agreements between ADP-Ag, PRI VASP and PRU were
etermined by linear regression (Pearson’s correlation coef-
cient) and Bland-Altman analysis. For each comparison,
greement between the two tests was calculated using the
appa statistic. A kappa statistic value of < 0.40 repre-
ents poor-to-fair agreement, a value of 0.41—0.60 reﬂects
oderate agreement, a value of 0.61—0.80 is considered
ubstantial agreement, and a kappa value of 0.81—1.00 is
onsidered excellent agreement. P < 0.05 was considered
igniﬁcant.
esults
total of 70 consecutive patients who fulﬁlled the enrol-
ent criteria were prospectively included. Demographic
ata of the studied population are summarized in Tables 1.
latelet testing was performed in all the patients after one
onth, receiving 150mg clopidogrel.
lopidogrel response with different tests
he mean values of platelet parameters were: 53± 17% for
DP-Ag, 42± 19% for PRI VASP and 199± 104 for the PRU
ith the Verify Now assay. The rates of non-responders
ith different tests were respectively: 13% (n = 9) with
he ADP-Ag (ADP-Ag > 70%), 39% (n = 27) with the PRI VASP
PRI VASP > 50%) and 33% (n = 23) with the Verify Now
ssay (PRU> 240). The demographic, clinical and thera-
eutic parameters were similar between responders and
on-responders whatever test is chosen (data not shown).
greements between different tests (Fig. 1)
inear regression revealed a good correlation between dif-
erent platelet tests assessing clopidogrel response:
ADP-Ag and PRI VASP (Y = 9,1923 + 0,6257X, r = 0.55,
p < 0.0001);
ADP-Ag and PRU (Y =−11,6388 + 3,9888X, r = 0.64,
p < 0.0001);
PRI VASP and PRU (Y = 64,4765 + 3,1868X, r = 0.59,
p < 0.0001).
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tigure 1. Correlation and agreement between different platele
ndex VASP (PRI VASP) and PRU assessed with Verify Now assay (PRU
The Bland-Altman plot showed a mean difference of 10.6
or ADP-Ag and PRI VASP, −146 for ADP-Ag and PRI VASP and
157 for PRI VASP and PRU (Fig. 2).
oncordance of different tests to identify
on-responder patient
he correlation was signiﬁcant as continuous variables, but
sing the most common threshold, the agreement between
he difference tests was weak: kappa = 0.35 for ADP-Ag and
RI VASP, 0.36 for ADP-Ag and Verify Now Assay and 0.46 for
RI VASP and Verify Now Assay. We repeated this analysis
ith another cut-off value for ADP-Ag of 50%. The analysis
ith 50% resulted in slightly better concordance between
ifferent assays: kappa = 0.42 for ADP-Ag and PRI VASP and
.52 for ADP-Ag and Verify Now (Fig. 3).
n
1
a
cameters with ADP-induced aggregation (ADP), Platelet Reactivity
iscussion
his study showed that assessment of platelet function inhi-
ition by clopidogrel is highly test-speciﬁc. Indeed, our
esults demonstrated a poor agreement between differ-
nt platelet assays to identify clopidogrel non-responders,
uggesting a probable need for a ‘‘double test’’ assess-
ent to identify a non-responder patient before tailoring
ntiplatelet therapy. Moreover, these results showed that
he rate of non-responders is very different with the three
latelet function tests. This could have a great impact in
aily practice for identifying the appropriate candidate for
ailored therapy. The PRI VASP identiﬁed as high as 39% of
on-responder patients despite a high maintenance dose of
50mg with a threshold of 50%. This cut-off value is prob-
bly too sensitive while large randomized trial showed a
lear beneﬁt of clopidogrel for ischemic events prevention,
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not suggesting that half the patients are ‘‘non-responders’’.
Biological studies have demonstrated a broad interindivid-
ual variability of platelet response to clopidogrel associated
with increased risk of ischemic events [1—9]. Several mech-
anisms have been proposed to explain this variability of
response including genetic factors, metabolic parameters or
interaction with other medications [1]. The active metabo-
l
i
f
oigure 3. Agreements between different platelet tests.
ite of clopidogrel, which irreversibly blocks platelet ADP
2Y12 receptors, arises from complex biochemical reac-
ions involving several CYP450 isoforms [10]. Accordingly,
enetic variations affecting the cytochrome activity will
herefore modify clopidogrel response as recently demon-
trated [11,12]. In addition, interaction with medications
etabolized by the cytochrome have been described, such
s atorvastatine [13], omeprazole [14] or calcium-channel
lockers [15]. Deﬁnition of clopidogrel resistance is not
onsensual and different platelet tests have been pro-
osed to assess clopidogrel response [1]. It was in the ﬁrst
eports mainly based on the ADP-induced platelet aggre-
ation [1]. However, platelet aggregation could have some
imitations: it is a non-speciﬁc method to measure the
nhibitory effects of clopidogrel, as it is mediated by many
actors, including multiple ADP-receptor pathways, while
nly one of these receptors is inhibited by clopidogrel.
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onetheless, it is most likely that ADP-induced light trans-
ittance aggregometry reﬂects at least some aspects of
latelet in vivo behaviour. Therefore, clopidogrel resistance
hould be strictly deﬁned from a speciﬁc laboratory point
f view: as an inability to achieve the expected inhibition
f the solitary target P2Y12 receptor. Fortunately, platelet
unction assays have recently been introduced to measure
he P2Y12 pathway. Indeed, a ﬂow cytometric VASP phos-
horylation assay has been introduced to measure more
peciﬁc inhibition of clopidogrel’s biochemical target, the
2Y12 receptor [16]. It has been investigated in both bio-
ogical and clinical studies [5,6]. The clinical relevance of
lopidogrel non-response underlines the necessity to opti-
ize the degree of platelet inhibition at the time of PCI.
everal strategies have been proposed to improve clini-
al prognosis of these ‘‘non-responder’’ patients including
igher clopidogrel loading dose [17,18], additional repeated
oading doses [19] or GPIIbIIIa antagonists [20]. However,
his tailored approach requires consensual deﬁnition of
on-response and validation of point-of-care platelet assay
sable in daily clinical practice is a prerequisite for such
ailored antiplatelet therapy. Accordingly, a recent point-
f-care Verify Now has been proposed and associated with
linical prognosis after PCI [7—9]. However, concordance
f these different tests has not been well investigated
n ACS patients. The level of correlations in our study is
uite low as compared with previous studies [21]. This
ight be explained by different platelet parameters (max-
mal platelet aggregation rather than residual), chronic
herapy evaluation, unstable patients or high maintenance
ose. Although the use of correlation to report on the
ssociation between two measurements is widespread, it
s often inappropriate as it does not imply agreement.
he present study showed that despite signiﬁcant corre-
ation, agreement is poor, and many patients identiﬁed
s non-responders with one test will be good responders
ith another one. This may suggest that concordance of
wo tests is probably needed before identifying a patient
s a non-responder and modifying his antiplatelet ther-
py. Indeed, the ideal platelet test must be reliable and
alid, with well-deﬁned diagnostic cut-off values, and treat-
ent decisions based on such tests should cost-effectively
mprove patient outcome. No laboratory or point-of-care
latelet function tests currently fulﬁls all of these cri-
eria. In a near future, platelet function testing could
elp to determine which patients would derive the most
eneﬁt from newer, more powerful P2Y12 inhibitors, such
s prasugrel. Whether, genetic testing will have addi-
ional value for individualized therapy will also have to be
ddressed.
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